Importation and Circulation of Vaccine-Derived Poliovirus Serotype 2, Senegal, 2020–2021
Martin Faye
, Ousmane Kébé, Boly Diop, NDack Ndiaye, Annick Dosseh, Abdoulaye Sam, Aliou Diallo, Hamet Dia, Jean Pierre Diallo, Ndongo Dia, Davy Evrard Kiori, Ousmane Madiagne Diop, Amadou Alpha Sall, and Ousmane Faye
Author affiliations: Institut Pasteur de Dakar, Dakar, Senegal (M. Faye, O. Kébé, H. Dia, N. Dia, D.E. Kiori, A.A. Sall, O. Faye); Ministry of Health and Social Actions, Dakar (B. Diop, A. Sam, J.P. Diallo); World Health Organization Inter-Country Support Team for Western Africa, Ouagadougou, Burkina Faso (A. Dosseh); World Health Organization Senegal Country Office, Dakar (A. Diallo); World Health Organization, Geneva, Switzerland (O.M. Diop)
Main Article
Figure 1
Figure 1. Temporal distribution of enterovirus isolates detected in Senegal during 2015–2021. A) Enteroviruses detected from acute flaccid paralysis surveillance, including all human specimens (cases, close contacts, and community contacts). B) Enteroviruses detected from environmental surveillance. cVDPV2, circulating vaccine-derived poliovirus serotype 2; NPEV, nonpolio enterovirus; PV-SL, Sabin-like poliovirus.
Main Article
Page created: August 11, 2022
Page updated: September 20, 2022
Page reviewed: September 20, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.